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Abstract 
We characterise cognitive function in two neurodegenerative metabolic diseases where cognitive 
effects have been considered mild or non-existent.  We asked whether cognitive effects were present 
and whether the cognitive effects of neurodegeneration were hetero- or homogeneous across diseases. 
Thirteen Morquio syndrome patients, 11 Tyrosinemia Type III patients and 104 controls were assessed 
using tasks for attention (simple RT, feature and conjunction visual search), language (BPVS, BNT) 
and oculomotor function (fixation, pro-saccade, anti-saccade, smooth pursuit).  There were different 
patterns of deficits.  In Morquio syndrome, visual search was slow, differences did not increase in 
proportion to display sizes and were not driven by the longest reaction times in the distirbution.  In 
addition, maintaining gaze on a target in an oculomotor task was difficult.  These patterns point to 
problems with control processes for attention. Language was relatively spared.  In Tyrosinemia Type 
III, in contrast, there were modest effects in attention, but language was clearly affected, and effects 
increased with age.  Both diseases presented clear evidence of cognitive effects, but with different 
functional profiles. The different markers (attentional control in Morquio and language in Tyrosinemia) 
are good candidates for disease tracking and for establishing functional/biological links and they 
suggest that there may be stronger impacts in different regions of the brain (frontal vs temporal areas). 
Keywords: Morquio, Tyrosinemia, inherited metabolic disease, language, attention, 
developmental disorder 
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Markers of cognitive function in patients with mild metabolic disease:  Morquio Syndrome 
and Tyrosinemia Type III  
Inherited metabolic diseases (IMDs) are large and heterogeneous class of genetic disorders that 
are caused by dysfunction within a single pathway of intermediary metabolism. In the majority of these 
diseases the dysfunction of metabolic enzymes leads to the accumulation of toxic metabolites, 
disrupting the normal development of multiple systems. The severity of symptoms associated with 
IMDs can vary widely. Mild symptoms can include physiological abnormalities such as skeletal 
dysplasia and impaired endurance (Davison, Kearney, & Horton, 2013; Wraith, 2006). Severe 
consequences include mental retardation, central nervous system (CNS) complications, and reduced life 
expectancy (Bendadi et al., 2014; De Laet et al., 2011; Masurel-Paulet et al., 2008; Thimm et al., 2011, 
2012). Research into the cognitive impact of IMDs has largely been limited to standardised intelligence 
tests, achievement tests and adaptive behaviour scales (Bax & Colville, 1995; Biernacka, Jakubowska-
Winecka, & Tylki-Szymanska, 2010; Davison et al., 2013; Shapiro et al., 2009), that are not suitable for 
characterising impairments in specific cognitive domains or accurately tracking impact over time  
(Martin et al., 2008). In the current study we present results from two IMD groups, Morquio syndrome 
and Tyrosinemia type III, where cognitive impairments have been considered mild (using standardised 
tests).  We evaluate Morquio and Tyrosinemia type III patients against the developmental trajectories 
defined by a sample of typically developing controls (Thomas, Annaz, & Ansari, 2009) to  characterise 
specific patterns of affected and preserved cognitive abilities. We concentrate on the domains of 
language, attention and oculomotor control. 
 
Morquio Syndrome (MPS-IVa , OMIM 253000)  
 Morquio syndrome (MPS-IVa) is lysosomal storage disorder that is caused by the 
deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfase (GALNS, EC 3.1.6.4; encoded by 
GALNS gene at 16q24.3) which has a role in the sequential degradation of the glycosaminoglycans 
(GAG) keratan sulphate and chondroitin-6-sulfate (Neufeld & Muenzer, 2001; Wraith, 2006). Both 
keratan sulphate and chondroitin-6-sulfate are essential constituents of connective tissue, including 
cartilage and vessel walls. The resultant accumulation of these two GAGs leads to a classic phenotype 
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defined by severe skeletal dysplasia, hip dysplasia, marked short stature, genu valgum, and cornea 
clouding (Hendriksz et al., 2013; Wraith, 2006). Treatment to reduce substrate burden in MPS-IVa 
include enzyme replacement therapy (ERT) and haematopoietic stem cell transplantation (HSCT) as a 
means to alleviate the majority of the skeletal and coronary complications. 
In contrast to other lysosomal storage disorders (e.g. Hurler-Scheie syndrome, Hunter’s 
syndrome, Niemann-Pick Type C), MPS-IVa patients have been reported to have no neurological or 
neurocognitive impairments (Dvorak-Ewell et al., 2010; Wraith, 2006) and neuroimaging results 
typically find no neuroanatomical abnormalities (Koto, Horwitz, Suzuki, Tiffany, & Suzuki, 1978). 
However, recent neurocognitive findings (Davison et al., 2013) from 8 MPS-IVa patients (aged 5 -17 
years) suggested that mild / borderline cognitive impairments do exist. Age appropriate standardised 
intellectual tests (e.g. WASI, WISC) revealed full scale IQ scores either in the lower average range (80 
– 90), borderline range (70 – 80), or extreme low range (<70) in 4 patients. The remaining 4 patients 
obtained normal Full Scale IQ scores (85 – 115). Attention problems in the majority of children were 
reported by parents using the Child Behavioural Checklist.  
Mild cognitive impairments in MPS-IVa were further supported by MRS findings in the same 
study. In 3 patients with cognitive impairments there was a correlation between white matter metabolite 
concentrations (N-acetylaspartate) and cognitive indices. In addition, MRI findings revealed 
neuroanatomical abnormalities which were apparent in more than half the patients. These included mild 
asymmetry of the lateral ventricles, prominent perivascular spaces and high signal white matter areas of 
the right frontal lobe.   Unlike the MRS findings, there was no correlation with cognitive indices, but 
this could be because the behavioural measures lacked sensitivity.  A formal assessment of attention is 
needed, especially in the context of the attentional difficulties reported by parents.   
Tyrosinemia Type III (T3, OMIM 276710) 
Tyrosine is an amino acid that is catabolised through the tyrosine metabolic pathway into fumarate 
and acetoacetate, both of which are important for gluconeogenesis and ketogenesis. Dysfunction at one 
of the sequential enzymatic reactions of this pathway will lead to one of the 3 identified 
hypertyrosinemia disorders: tyrosinemia types I to III, which result in the accumulation of plasma 
tyrosine levels and increased urine excretion of tyrosine (Chakrapani, Gissen, & Mckiernan, 2012). For 
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example, tyrosinemia type I is caused by the deficiency the fumarylacetoacetate hydrolase, the final 
enzyme in the tyrosine catabolic pathway, which results in an accumulation of the highly toxic 
metabolites fumaryl- and maleylacetoacetate in the liver. As a result, patients experience organ 
dysfunction and carcinogenesis, with hepatocellular carcinoma a frequent cause of death in childhood. 
Tyrosinemia type II, results from a defect in tyrosine transaminase, the first enzyme in the tyrosine 
pathway and effects, in particular, the eyes and skin, but also mental development. 
Tyrosinemia type III (T3) is caused by the deficiency of 4-hydroxyphenylpyruvate dioxygenase, 
the second enzyme within the tyrosine metabolic pathway. There is an extreme accumulation and 
increased excretion of tyrosine, but not an increase in the same toxic metabolites (fumarylacetoacetate) 
that occur from enzyme defects later in the pathway (Chakrapani et al., 2012; Scott, 2006). Treatment of 
T3 patients consists of a low-protein diet and administration of ascorbic acid to control tyrosine levels 
(Scott, 2006). In contrast to tyrosinemia type I, T3 is a more benign form, not associated with the liver 
or renal complications which lead to reduced life expectancy.  
T3 is the rarest of the three tyrosinemia disorders and the effects of elevated concentrations of 
tyrosine in the central nervous system are not well established. Only 15 cases have been reported in the 
literature to date (Ellaway et al., 2001; Heylen et al., 2012; Szymanska et al., 2015). However, 
neurological and intellectual difficulties are commonly reported characteristics. A review of T3 patients 
by Ellaway et al. (2001) provides the best description of cognitive functioning for a collection of T3 
patients (13 patients). Eight out of 13 patients demonstrated neurological symptoms such as 
developmental delay or mental retardation, attention deficit and behavioural disturbance, acute ataxia, 
tremor, hypotonia and absent deep tendon reflexes. The most common long-term complication was 
intellectual impairment, found in 75% of reported cases (Ellaway et al., 2001).  It was speculated that 
impairment results from neurotoxic effects linked to elevated tyrosine levels. The results, however, are 
based on aggregated scores from tests that are not designed to distinguish specific types of cognitive 
impairment (e.g. e.g. Stanford-Binet, WISC, WASI), so further research is required to determine how 
specific cognitive capacities are affected.  
Further evidence of cognitive impairment in T3 comes indirectly from research with T1 patients 
who have been treated with 2-nitro-4-trifluromethylbenzoyl (NTBC).  NTBC gives T1 patients the 
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biochemical profile of T3 patients by inhibiting the enzyme 4-hydroxyphenylpyruvate dioxygenase.  
This greatly increases T1 patient survival by preventing the subsequent accumulation of toxic 
metabolites that affect the liver and renal systems, but elevates tyrosine concentrations as a side-effect. 
T1 is a more common form of tyrosinemia and, in contrast to T3, more detailed reports of 
neurocognitive function in this group exist (Bendadi et al., 2014; Thimm et al., 2011; Van Ginkel et al., 
2016)  Using age-appropriate test batteries, different studies have documented lower IQ scores and 
specific language production and comprehension impairments in NTBC-treated T1 patients (Bendadi et 
al., 2014; Thimm et al., 2012). The most detailed description of cognitive function in T1 was recently 
provided by (Van Ginkel et al., 2016), measuring nineteen NTBC-treated patients with both age-
appropriate psychometric tests (e.g. WISC and WASI) and additional measures of executive 
functioning. Lower average IQ performance (median 85: range 55 – 111) were reported. Executive 
function tests revealed specific working memory deficits (in reaction time and error rates) in T1 patients 
when compared to age-matched controls. Inhibition was also assessed but no differences were found 
between patients and controls. The cognitive deficits from the T1/NTBC studies could be due to the 
elevated neurotoxic levels of tyrosine that are a side effect of NTBC therapy, but they could also be a 
direct effect of NTBC (Van Ginkel et al., 2016).  Results from T3 patients will help to clarify this issue. 
Based on these previous findings (Bendadi et al., 2014; Ellaway et al., 2001; Thimm et al., 2012; 
Van Ginkel et al., 2016), we expect to see some cognitive impact in tyrosinemia type III resulting from 
high levels of tyrosine.  As with Morquio Syndrome, however, we will characterise, in more detail, 
capacities which are affected and preserved. 
Methods  
Participants 
Morquio Syndrome (MPS IVa) and Tyrosinemia Type III (T3) 
Thirteen patients diagnosed with Morquio syndrome (8 male; mean age: 9.59 years, range: 5.27 
– 14.39 years) and eleven patients diagnosed with tyrosinemia type III (3 male; mean age: 12.53 years, 
range: 4.40 – 19.58 years) were recruited at Birmingham Children’s Hospital, UK (demographics in 
Appendix 1). Diagnosis in Morquio patients was confirmed via genetic testing, all were considered to 
have a severe phenotype of the disease, but no patient presented with corneal clouding and none was 
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ventilated. Diagnosis of Tyrosinemia Type III was confirmed via genetic testing after elevated tyrosine 
levels were detected during newborn screening. All patients were native English speakers.  A number 
were bilingual (see Appendix 1).  Both patient groups were tested in 2012-13 at the Wellcome Trust 
Clinical Research Facility at the Birmingham Children’s Hospital. Consent was obtained from 
parents/guardians prior to testing. 
Typically Developing Controls (TD) 
 To compare patients with typically developing controls (TD), we used a developmental 
trajectory approach.  We tested a large sample of controls across a range of ages between 6 and 20 to 
establish the trajectory of typical development in each cognitive domain (Attention tasks N = 104, 
Language tasks N = 104, Oculomotor tasks N = 265).  Prior to testing, informed consent was taken from 
undergraduate student participants or from parents of child participants. 
Apparatus & Procedure 
We used a battery of neuropsychological tests in three cognitive domains:  language, attention 
and oculomotor control. Patients took took approximately 1 – 1.5 hours to complete the battery, 
depending on ability and need for breaks.  
Attention and oculomotor function were assessed with computerised tasks created using 
Experiment Builder (SR Research Ltd., Mississauga, Ontario, Canada). Participants viewed stimuli 
from 60 cm on a 36 x 27 cm CRT-monitor with a resolution of 1024 by 768 pixels and a refresh rate of 
60Hz, producing a viewing area of 33.5° x 25.5° (width x height) of visual angle. Reaction time (RT, 
measured in milliseconds, msec) for manual responses were recorded using a Cedrus button box 
(http://cedrus.com/). Language tasks were table-top tests. 
Eye movements were recorded via an EyeLink® 1000 Tower Mount (SR Research Ltd., 
Ontario, Canada). The location and duration of fixations are measured using corneal reflection via an 
infrared camera. Head movement was minimized using a forehead and chin rest. Eye movements were 
calibrated to an accuracy of at least 1⁰ using a nine-point calibration array. Drift correction was 
employed before each trial. Participants were recalibrated if measured fixation of a central point was 
inaccurate. Saccade detection was based on default Eyelink 1000 settings (19-sample window): samples 
were classified as part of a saccade if eye velocity exceeded 22⁰/second and eye position changed more 
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than 0.3
 ⁰, otherwise samples were classified as fixations. Prior to analysis trials from all tasks were 
visually inspected to ensure that participants were engaged in the task and  artefacts had been removed.  
Attention tasks 
Attention was measured with a simple reaction time and visual search task. We familiarised 
participants with the visual search targets (red ladybirds) by introducing them in the simple reaction 
time task, which was always presented first. 
For simple reaction time we measured speed to respond to appearance of a visual target. 
Participants completed 20 trials where a red ladybird (5.5° x 7.5°) was presented in a box in one of the 
four quadrants around the centre (upper left, upper right, lower left, lower right; box size = 10° x 9°; 12° 
diagonal distance from screen centre). The target appeared in each quadrant 5 times, with the order of 
the target locations randomised b tween participants. Each trial began with a centrally presented 
fixation cross (1° x 1°), after a variable delay of 1500 – 4000ms the red ladybird target stimulus was 
presented in one of the four quadrants. Participants were instructed to respond with their preferred hand, 
using a single button press, as quickly as possibl  after the target appeared. The stimulus remained on 
the screen until the participant made a response or for 3000ms.  There was an inter-trial interval of 
1000ms prior to the presentation of the fixation cross for the following trial. 
  The visual search task consisted of 3 feature search blocks and 3 conjunction search 
blocks. In all blocks participants indicated whether the red ladybird target character was present with a 
“Yes” button-press, or absent using a “No” button-press. Feature search asked the participants to search 
for the red ladybird among a set of green ladybird distracters. The target was defined by colour only.  
Conjunction search asked participants to search for a red ladybird among green ladybirds and red beetle 
distractors. The target is defined by a conjunction of colour and shape, since neither identifies the target 
in isolation (Eckstein, 2011; Treisman & Gelade, 1980).  Each block contained 12 trials with 3 display 
sizes (4, 8, and 12 items). The target was present in half the trials in each block, and absent in the other 
half. Block order was randomised between participants. Search displays were created by dividing the 
screen into a 4 x 4 grid (each grid location = 8.5° x 6.5°). Search items (4° x 5° of visual angle) were 
randomly assigned to the 16 grid locations. In order to make displays less regular, each item’s position 
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was jittered by a random amount (x maximum ±2° and  y maximum ±1°).  For target-present 
conjunction trials one red beetle distractor was replaced with the target to ensure the number of red and 
green elements were equal. 
Each trial began with a centrally presented fixation cross for 1000ms, followed by the stimulus. 
Participants used a Cedrus button box to make a response (left button = target absent; right button = 
target present). Stimuli disappeared after a response or if no response was registered within 10 seconds. 
A blank screen was displayed for 1000ms prior to the following trial. At the beginning of each block 
participants were informed of the block type (feature or conjunction). Targets and distractors were 
shown on screen and verbal instructions given by the experimenter. There were four practice trials with 
feedback, at the beginning of the experiment, to familiarise participants with the task.   
Response times for correct responses were used to calculate an overall visual search response 
time and a measure of visual search efficiency. Search efficiency was defined as slope of the change in 
RT with increasing display size, i.e. the change in response speed as a function of display size. When 
search efficiency is zero, RT does not increase with display size. Values above zero indicate that 
additional items in larger displays take more time.  Feature search normally has a search efficiency near 
zero because targets “pop out” regardless of the number of distractors.   
Language tasks 
Measures of verbal production (Boston Naming Task or BNT; Kaplan, 2000) and 
comprehension (British Picture Vocabulary Scale or BPVS; Dunn et al., 1997) were used to assess 
children’s language abilities.  
The BNT is a 60-item picture naming test with items that increase in difficulty.  If a participant 
was unable to name an item, a semantic cue was offered.  A phonetic cue was provided if the semantic 
cue failed to produce a correct response. An item was counted correct if the participant was able to 
produce the name with or without a semantic cue, and incorrect if the participant failed to produce the 
name or produced it after a phonetic cue. The test finishes if participants make more than 5 consecutive 
errors. 
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The BPVS is a receptive vocabulary test. Participants listen to a word and select a matching 
picture from four line drawings.  There is no spoken response.  There were 14 sets of 12 items which 
increase in difficulty. The test is terminated if there are eight or more errors on a single set.  
Oculomotor function tasks 
 Oculomotor function was tested using two paradigms: a fixation and pro-saccade task 
(Fischer & Weber, 2010; Klein, 2001; Munoz & Everling, 2004; Salman et al., 2006).  These tasks 
assess distinct components of the saccadic eye movement system and frontal executive functions that 
contribute to oculomotor control (e.g. inhibition and sustained attention during fixation).  
Fixation Task 
In the fixation task, participants were asked to fixate a central target, move their eyes to follow 
the target when it moved to one of four possible positions and then maintain their gaze until the target 
disappeared.  There were 20 trials.  An elephant face target (1.5
 ⁰ in size) appeared in the centre of the 
screen and then moved to a location 10⁰ to the left, right, above or below the central fixation point. 
Possible target locations were marked with small circles (0.5 ⁰ in size) to indicate where the target might 
appear. Trials began with the presentation of the target centrally for 1000 milliseconds (msec). The 
target disappeared and immediately reappeared (no gap or overlap) randomly at one of the four 
surrounding locations. The target remained at this location for 5000ms and participants were asked to 
maintain fixation on the target until it disappeared.  A 3 x 3° box surrounding each target was defined as 
a region of interest (ROI) and fixations within the ROI were counted as fixations on the target. Dwell 
time was defined as the length of time participants maintained eye position within the target’s ROI 
(FixDwell). The frequency of saccades away from the target (greater than 2°) that moved the 
participant’s gaze outside the target ROI were also measured (FixSacc). 
Pro-saccade Task 
Participants viewed 48 trials where a target elephant face (1.5⁰ in size) randomly appeared at 
one of eight positions around a central starting position. The four locations from the fixation task were 
used (see above), along with four additional locations, closer to the centre (eccentricity = 5⁰). Each trial 
began with the stimulus appearing at the centre of the screen for a random amount of time between 
1000 and 2000ms. The stimulus then disappeared and reappeared at one of the possible target locations 
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for 1000ms without any gap or overlap. Participants were asked to look as quickly and accurately as 
possible directly at the target.  
To be included in the analysis, saccades had to start at the centre of the screen and the eye 
movement had to be toward the peripheral target. We measured the onset of the first movement toward 
the target and its peak velocity.  Only data from targets at 10⁰ are presented here. 
Data Analysis 
Measures that were greater than 3 SDs away from individual participant means were defined as 
outliers and removed.  Patients and typically developing (TD) control children were compared using a 
developmental trajectory approach (Thomas et al., 2009).   Developmental change was modelled as a 
linear or quadratic function of age. We were interested in differences in the rate of developmental 
change (differences in the slope of trajectories) and differences in absolute levels of performance 
(offsets between patient and control trajectories). We fit linear mixed effects models (LME) with fixed 
factors for Group, Age and Condition (e.g. target location). Main effects of Group or Condition 
indicated higher or lower performance across all ages. Interactions with Age indicated that the rate of 
developmental change differed either between patients and controls (e.g. Group X Age), or between 
conditions (e.g. Condition X Age), or that there were condition-specific trajectory differences between 
patients and controls (e.g. Group X Age2 X Condition). Akaike’s Information Criterion (AIC) was used 
to compare models (Burnham & Anderson, 2002).  AIC is preferred for model comparison because, 
unlike likelihood ratio p-values, AIC balances fit and the number of model parameters when choosing 
models.   
Model selection using AIC is different from p-values, but not difficult to understand.  In brief, 
better models produce smaller AIC values, but the absolute AIC values are not interpretable.  Instead, 
the change in AIC (∆AIC) between models is meaningful and captures the weight of evidence for each 
model (rather than being subject to a cut-off, like p-values).   Evidence for a model starts to be clear if 
the ∆AIC exceeds 2. If ∆AIC between the “best” model and alternative models is less than 2 then the 
two models are substantially equivalent. When ∆AIC is between 2 and 10 there is decreasing support 
for an alternative model.  A model with a ∆AIC > 10 has essentially no support.  For models where the 
∆AIC is less than 2, it is reasonable to favour the least complex model (i.e. model with fewest 
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parameters/variables).  Comparisons can be assisted by calculating Akaike weights (AICw; Burnham & 
Anderson, 2002).  AICw expresses the relative probability that a model is the best in a particular set, 
considering only the models from that set. It measures the weight of evidence for the models being 
compared.  When values are relatively equal across two or more models, they are all relatively good 
models of the data.  If one model has a high value and the others are low, there is a model that is clearly 
better.  Favoured models contain the terms that would be significant in a traditional analysis.  For 
example, if a highly-rated model has a term for Group but no interaction, this corresponds to a 
traditional analysis where the main effect of Group is significant and there is no interaction.   
We report results from a large sample of controls and a much smaller sample of patients, as in 
inevitable in the study of rare diseases.  This means that models that do not involve the Group term are 
largely determined by the data from normally developing control participants.  We model control data 
without patients initially to characterise normal development.  When we report results from patients and 
controls we will concentrate on evaluating the influence of the term for Group. 
Because of possible heterogeneity among patients within groups we also compared individual 
patients to typically developing controls (TD).  The question was whether individual patients were 
inside or outside the range of typically-developing values.  To define the range of typically developing 
values, ninety-five percent prediction intervals were defined at each age, setting a point above and 
below the TD means.  Ninety-five percent of individual control values should fall between these points.  
Cutoffs for each age were smoothed to a boundary that applied across ages by fitting a curve to the set 
of upper or lower boundary points. This method minimises the impact of idiosyncratic estimates, 
smoothing the boundary position across ages by borrowing information from adjacent age groups.  
After defining limits, individual patients were compared to controls using the equivalent of z-scores, but 
using the upper or lower endpoints of the smoothed prediction intervals, rather than the noisier age-
specific prediction interval points. We label these zpi.1 
Results 
                                                     
1
 Specifically, for values above the mean,  = ( − )/1.96 and # = $%&'&/, 
where = upper boundary of the smoothed prediction interval; mean = the mean predicted by the fit to 
control values; and $%&'& = patient’s observed data value. Values below the mean were calculated in the same 
way except the 95% prediction interval boundary (()*) used the lower boundary since boundaries were not 
necessarily symmetric. 
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Table 1 summarises domains where Morquio (MPS-IVa) and Tyrosinemia (T3) patients had 
difficulties (shaded in grey).  The number of patients who performed worse than the control mean, 
worse that 1 SD from the control mean and worse than 2 SD from the control mean are listed.  MPS-
IVa patients displayed clear deficits on tasks with elements of attentional control: visual search and 
holding fixation. T3 patients exhibited clear deficits on language tasks (BNT and BPVS). Mild attention 
deficits were also observed (RTmean, VSmean, FixDwell) for T3 patients.  
________________ 
Table 1 about here 
________________ 
Attention tasks - Simple Reaction Time Task 
Typically developing Controls (TD) 
Reaction times were log transformed because, as is often the case, the raw RT distribution was 
right-skewed and a log transform produces a more balanced distribution. The best model describing the 
development of simple reaction time included an effect of age, distinct trajectories for targets presented 
to the left and right and an interaction. The majority of developmental change occurred during the first 
years of development, with little change after age 12 (~300 msec over the range from 6 to 12 years).  
Reaction times for younger children were 51 msec slower when targets were on the right of the screen 
(Figure 1) and then the difference decreases with age. 
_________________ 
Figure 1 about here 
__________________ 
Morquio patients (MPS-IVa) 
RT means for individual MPS-IVa patients are displayed in Figure 1.  They were within the 
confidence limits of healthy development for individual patients (0/12 with zpi > 2; black points inside 
dashed black line, Figure 1).  The group mean was shifted towards slower reaction times, with eleven of 
12 patients slower than the control mean, but not far enough to be outside the control range. 
In the analysis of group differences a model with a quadratic term for age was used because the 
developmental trajectory is curved, not linear.  The model with an Age
2 
X Condition interaction was 
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essentially equivalent to the best model (∆AIC = 0.23; best model: Condition X Age2 + Group X Age2).  
Evidence of differences between patients and controls was weak (AIC results for the best models of 
MPS-IVa patients and controls are summarised in Appendix 2).   
Tyrosinemia III 
 
Individual T3 patient RT means are displayed in Figure 2.  They were evenly distributed across 
the control range (solid grey lines) for all target locations. 
__________________ 
Figure 2 about here 
__________________ 
 Only three patients had response times that were reliably slower than controls (zpi > 2) when 
performance was averaged across target locations. These were the two youngest patients (patient 1 - 
4.40 years, patient 2 - 5.16 years) and an older patient (patient 9 - 17.64 years). One patient (Patient 11; 
19.10 years) was on the border (zpi = -1.98).  
 In group comparisons, the best model included a Condition X Age X Group interaction 
(AIC results for the best models for Tyrosinemia III patients and controls are summarised in Appendix 
3).  The effect of condition was not particularly strong.  A model with just main effects of Age and 
Group was nearly as good as the best model (∆AIC = 1.97).  There were, however, strong effects of 
Age and Group.   The first models without these terms had essentially no support (∆AIC=11.12 and 
∆AIC=17.19).  The 3-way interaction occurs because T3 patients are slower than the control mean at 
the earliest ages, closer to the mean in the middle of the age range and slow again when they are older, 
but by much less, and then the differences are somewhat different in the different quadrants.  These 
interaction effects are, however, subtle and the small T3 sample makes them uncertain.   The effect of 
group is stronger and occurs because 7/11 patients are slower than the control mean.  
Visual Search  
Typically developing Controls (TD) 
Mean reaction time is plotted in the top panels and search efficiency in the bottom panels of 
Figure 3.  TD controls increased their overall speed with age (top panels) in both conjunction and 
feature search.   The biggest change occurred during the early years, with changes slowing after about 
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10 years old.  Feature search times decreased with age, but were not longer for larger displays (i.e. 
efficiency did not change). Search efficiencies were close to zero at all ages (although there was some 
decline in variability). The best model included an effect of age but no effect of display size.  The best 
model of conjunction search included an interaction between display size and age.  The time to search 
each item declined steadily from around 70 to around 32 milliseconds (bottom right panel) over the 
range between 6 and 19 years.  There was also a large drop in variability.   
Accuracy supported the same pattern.  Accuracy in feature search increased across ages 
(from 94% at age 6 to 98% at age 19).  There was a difference in accuracy on present vs absent trials 
(90% vs 98% at age 6) that narrowed with age (99% vs 98% at age 19) and models supported an 
interaction between present/absent and age. There was no effect of display size. The best model of 
conjunction search accuracy included an interaction between display size and target present/absent and 
an interaction between age and present/absent.  The interaction with age was very weak because a 
model with just a main effect of age was nearly equivalent (∆AIC = 1.23).  The interaction with display 
sizes occurs because more targets are missed in larger displays.    Accuracy increased with age (85% at 
age 6 vs 97% at age 19).  These patterns do not modify the interpretation of the reaction time results 
(where larger displays take longer). 
_________________ 
Figure 3 about here 
__________________ 
Morquio Syndrome (MPS-IVa) 
The biggest difference between patients and controls occurred in the simpler task of feature 
search, although there was also some effect on conjunction search (Figure 3).  In feature search, zpi was 
> 2 in 6 patients and between 1 and 2 in one other patient.  Eleven of 12 patients were slower than the 
control mean.  Six would be expected by chance.  In conjunction search, zpi was > 2 in 3 patients and 
between 1 and 2 in 4 others.  Ten of 12 patients were slower than the control mean. 
General slowing was not usually associated with larger effects of display size. In feature search,  
searching additional items took longer in three individuals (Patient 1, zpi = 2.46; Patient 8, zpi = 5.99; 
patient 11, zpi = 11.25), and, in conjunction search, in two (Patient 8, zpi = 2.57; Patient 11, zpi = 3.55). 
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In sum, a substantial subset of the patient group were generally slower than controls, but only a much 
smaller subset produced disproportionate increases in search time as display size increased (2-3/12).  
For most patients the increase with display size was normal even if overall search times were shifted 
upward by a constant amount. 
Group differences between MPS-IVa patients and controls were analysed separately for feature 
and conjunction search.  The best model of feature search did not include an effect of Display Size in 
either patients or controls and there were no two or three-way interactions. The lack of a Display Size 
effect means that usually the search for a feature difference happens in parallel across all locations in 
the display no matter how many items there are to search, which is the normal pattern in feature search 
(Treisman & Gelade, 1980).  There were main effects for Age and Group.  Younger participants were 
slower.  The main result, for our purposes, was that patients were slower than controls (by 445ms).   
Terms for Group and Age were clearly necessary because models without these terms were poor.   
There was no interaction between Group  and Age, which means that, despite general slowing, 
patients make progress at a normal rate, neither catching up with controls or falling behind.  We need to 
be somewhat cautious about this result, however, because of the small number of patients at each age. 
In the analysis of accuracy, Group was added to the Age by Present/absent interaction from the 
control model.  Instead of the increasing accuracy for both present and absent trials seen in controls, 
MPS-IVa patients initially show a bias to "present" and later a bias to "absent" with little consistent 
change to percent correct.  This is not a theoretically important pattern in the present context. Averaging 
over present/absent conditions, the best model included an interaction between Age and Group that 
resulted from increasing overall accuracy in controls, but flat or slightly decreasing accuracy in patients.  
Patients and controls had equivalent accuracy when averaging across ages (both 94%).  The accuracy 
results do not change the interpretation of reaction times.  Accuracy is high in both patients and controls 
and there was no indication that longer RTs were associated with higher accuracy in the patient group 
(R = -0.46, p=.13; a negative R value results when higher accuracy is associated with lower RT). 
The top four models of conjunction search were all very similar in their ability to account for 
reaction times (Display size X Age + Group X Age; Display size + Group X Age; Display size X Age + 
Group; Display Size + Age + Group; max change in AIC = 0.8).  Good models all included terms for 
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Display Size, Age and Group.   Where there was an interaction between Group and Age, this resulted 
from MPS-IVa patients who were slower than controls being concentrated at older ages, but the effect 
was based on small numbers.  Some good models also included an interaction between Display Size and 
Age based on more efficient search at older ages.  All these interactions, however, were small effects 
because the simpler model with only main effects was a close equivalent (∆AIC=0.8).  It is important to 
note that there was no interaction between Display Size and Group.  Patients were as quick as controls 
to process each item, even when efficiencies were above zero, which shows that each item did require 
additional processing time. The display-size effect for both patients and controls was ~42 ms per item.   
The Group effect occurs because patients are ~378 ms slower than controls (for both large and small 
displays). Models without main effects of Display Size, Age or Group were poor.    
This overall pattern shows that patients were generally slower than controls, but differences 
were not concentrated on larger displays, which means patients did not have slower item-by-item 
processing. 
Once again, analysis of accuracy did not change this pattern.  The best model of accuracy was 
not different from the control model and did not include a term for Group. 
In sum, MPS-IVa patients were clearly slower in visual search.  This difference, however, was 
constant across display sizes.  Patients did not process each item in the search displays more slowly.  
The upward shift in reaction times without display size effects could have at least two origins.  One 
possibility is that patients occasionally lose concentration or are distracted.  If so, reaction times at the 
fast end of the range should be similar to controls, but there should be more difference in slower 
reaction times. Lapses could be distributed across trials with small and large displays.  A second 
possibility is that a stage that is always present, but not sensitive to the attentional demands of the 
display, is affected (e.g. a decision stage is one possibility).  This would result in higher reaction times 
across the full range of fast and slow times, not just a difference at the slow end of the scale.   
To explore these alternatives, we binned reaction times into quintiles for each participant and 
compared quintiles for patients and controls using the vincentizing method (Ratcliff, 1979; see Romani, 
MacDonald, De Felice, & Palermo, 2017 for this kind of analysis in a population of PKU patients).  
Figure 4 shows reaction times and standardised differences between means for patients and controls in 
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each quintile.  To standardise, we divided the difference between patient and control means by the 
standard error of the control mean.  Because reaction time distributions have an extended tail associated 
with the longest reaction times, the variance in the final bin, especially, is higher than in the other bins, 
and analysis of quintile differences needs to take this increased variance into account.   We will 
concentrate two aspects of the difference curves.  We ask if they are sloped upwards, particularly in 
quintiles 2, 3 and 4, showing increasing differences with longer reaction times.  We will also look at 
where patients means are slower than controls. 
_________________ 
Figure 4 about here 
_________________ 
The two possible sources of longer reaction times are well illustrated by comparing MPS-IVa 
and Tyrosinemia patients, as we will see below.  With two exceptions, the pattern in MPS-IVa patients 
is for relatively stable differences across the full range of quintiles, not increasing differences.  This is 
the case for feature search at ages 5-8, conjunction search at ages 8-10.5 and both feature and 
conjunction search at ages 10.5-14.5.  Conjunction search at ages 5-8 were not reliably different from 
controls in any bins (all t< 1.8, all p>0.08).    Feature search for ages 8-10.5 is the only condition where 
there were steadily increasing differences across the range of RTs.  Apart from the two exceptions 
noted, patient reaction times were always slower, even in the fastest bins (t>2.3; p<.03) and not 
consistently increasing.  The overall pattern does not support distraction/failures of attentional control 
or the accumulating effects of general slowing as the primary source of longer reaction times.  Instead, 
there appears to be a problem with processing at a stage that is not sensitive to the attentional demands 
of the task.  A decision stage is one possibility.   
Tyrosinemia III (T3) 
In feature search, four of eleven T3 patients had zpi  > 2. An additional two patients had zpi 
between 1 and 2 (Figure 5).  In conjunction search, five of eleven patients had zpi  > 2 and two patients 
had zpi between 1 and 2.  Search efficiency slopes had zpi  > 2 in only one patient and between 1 and 2 in 
three others. 
______________ 
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Figure 5 about here 
______________ 
Group differences were analysed separately for feature and conjunction search.  The best model 
for feature search included an Age by Group interaction.   There were more patients who were further 
from controls at older ages.  There was a ~76 ms difference between groups when participants were 
under 12 years old, with as many patients below the control mean as above it.  Patients older than 15 
years were, on average, ~187 ms slower than controls, and all four patients were above the mean.  There 
was no effect of Display Size, indicating that feature search was efficient for both groups. 
The best model for accuracy in feature search included an interaction between Present/absent, 
Age and Group, adding Group to the interaction from the control model.  As with MPS-IVa patients, 
Tyrosinemia III patients show a different pattern of Present/absent effects compared to controls.  
Accuracy is relatively constant, but Present trials show some decrease, mainly due to results from one 
patient.  What is more relevant, for our purposes, is that, overall, patients were less accurate than 
controls (89% vs 93%).  There was no evidence of a speed/accuracy trade-off that would modify 
interpretation of the reaction time results. 
In conjunction search, the best model of reaction times included main effects of Display Size, 
Group and Age, but no interactions.   The group difference was an average of 71 msec when 
participants were below 12 years old and 133 ms when participants were above 15 years old.  The lack 
of interactions with group shows that effects of Display Size and Age were not reliably different in 
patients compared to controls.  
Models of accuracy in conjunction search added an interaction with Group to the Display Size 
by Age by Present/absent interaction from the control model.  Present/absent differences were unstable 
in patients because of the small number of individuals and they are not theoretically important.  We 
accumulated over present/absent conditions and put patients into only two age groups (less than or 
greater than 12 years old) to increase N.  Models still required a Group by Display size by Age 
interaction.  Tyrosinemia patients were generally less accurate than controls (80% vs 90%) and the 
display size effect was larger in younger patients only (accuracy dropped by 12% when young patients 
viewed larger displays, but only by 1-3% in older patients, young controls and old controls).  
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Results from analysis of reaction time quintiles showed that differences between patients and 
controls concentrated on longer reaction times (Figure 6).  At ages 4.5-6, differences in both search 
tasks increased in bins 1-3 and then levelled out.  At ages 6-8.5 patients were not slower than controls.  
At ages 15-19, differences increased across all bins in both search tasks.  In the youngest and oldest 
patients, reaction times were different even in the first bin (all t> 2.3; p<.03), showing that patients in 
these groups were always slower, but the differences increased for longer reaction times.  Different 
patterns at different ages should be interpreted with caution because the number of patients at each age 
is small and individual vs. age-related differences cannot be clearly separated. 
_____________ 
Figure 6 about here 
_____________ 
In sum, considering both accuracy and reaction time together, effects on accuracy were more 
pronounced for younger patients, but reactions times slowed more in older patients.  Differences in 
visual search, in other words, were sometimes observed more in accuracy and sometimes more in 
reaction times, but there was a relatively consistent difference.. Turning to the level of individual 
patients, there was considerable variability.  Some patients showed clear differences, and others did not. 
Seven of 11 individuals recorded reaction times that were slower than controls in feature search and 
seven of 11 in conjunction search (not always the same individuals).  This is not a marked difference 
from controls because the value expected by chance is 5.5.   By way of contrast, in MPS-IVa feature 
search the whole group was shifted up in relationship to control values, with nearly all MPS-IVa 
patients above the control mean.  There was some indication that Tyrosinemia III patients get worse 
with age, but this was a preliminary result that should be treated with caution.  It was based on small 
numbers, so that patient-specific effects will be difficult to distinguish from a general effect of age. 
Language  
Typically developing Controls (TD) 
 Control participants showed clear effects of age in both the BPVS (∆AIC = 163) and the 
BNT (∆AIC = 58).   There was improvement across the range of ages tested (Figure 7). 
________________ 
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Figure 7 about here 
________________ 
Morquio Syndrome (MPS-IVa) 
All MPS-IVa patients completed the British Picture Vocabulary Scale (BPVS). Patient 12 did 
not complete the Boston Naming Test (BNT) because of time constraints.  Individual BPVS and BNT 
scores are shown in Figure 7. Two individual patients had zpi  that was reliably different from controls 
on the Boston Naming Test;  one below the control mean (patient 6; zpi = -3.17) and one above (patient 
7; zpi = 2.74). Three other patients had zpi between -1 and -2. The best model for the Boston Naming 
Test included only a term for changes with age.  There was no evidence that MPS-IVa patients 
produced systematically lower BNT scores than controls. 
No BPVS scores had zpi  < -2, but 7/12 patients were between -1 and -2 (Figure 7).  The best 
model for BPVS scores included an interaction between Group and Age, but evidence for the interaction 
was weak because the model without the interaction was nearly equivalent (∆AIC = 0.7).  The 
estimated score difference between Morquio patients and controls was -9.4 points (based on the model 
without an interaction). 
In sum, MPS-IVa patients showed no difference from controls in productive vocabulary and 
only minor differences in receptive vocabulary with very few or no patients outside the control range on 
either task. 
______________ 
Figure 8 about here 
______________ 
Tyrosinemia III (T3) 
Just over half of the T3 patients were more than 2 zpi below controls on the BNT (6/10 patients).   
The best model for BNT results included an interaction between Age and Group.  The difference 
between patients and TD controls widened with age (Figure 8).  The difference at the earliest ages was 
18, but widened to 56 in the oldest patients.   
The majority of patients were more than 2 zpi below controls on the BPVS (zpi < -2; 8/11 
patients).  Similar to BNT results, the best model included an interaction between Age and Group.  Once 
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again, the difference between T3 patients and TD controls got larger with age (Figure 8).  At the earliest 
ages (6 years) the estimated difference was 32 points.  By 19 the estimated difference had grown to 63 
points.  Models without terms for either Age or Group were poor. 
Unlike MPS-IVa, where the differences between controls and patients were small, T3 patients 
show clear problems with language tasks that become more marked with age. 
Oculomotor Tasks 
Oculomot r tests included a fixation task and a saccade task.  Morquio patients 5 and 7 did not 
want to attempt the saccade task and patients 2, 3, 4 and 11 did not complete all the saccade trials due to 
fatigue. T3 patient 2 was unable to complete the oculomotor tasks due to postural difficulties which 
prevented eye tracking. 
Fixation Task – Dwell Time 
Typically Developing Controls 
 Typical development of fixation dwell time was described best by a quadratic model that 
included an interaction between Condition and Ag . Systematic checking of location revealed that the 
model was improved by having a distinct trajectory for the top target condition, with a shared trajectory 
for left, right and bottom targets (Separate Condition Model, ∆AIC = 0.87; AICw = 0.39 ; Top 
Condition Model, ∆AIC = 0.00; AICw = 0.61). This means that typically development occurs at a 
different rate for top targets in comparison to targets presented in the other three locations. Figure 9 
shows that is largely due to differences between target conditions at the youngest ages (5 – 6 years) 
where participants are able to hold fixation on top targets longer than left, right and bottom targets (max 
4345 ms top vs min 3903 bottom). 
 
 
__________________ 
Figure 9 about here 
__________________ 
Morquio Patients (MPS-IVa) 
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The majority of MPS-IVs patients exhibited fixation dwell time deficits (zpi < - 2) for the left 
(7/11 patients), right (8/11), and bottom target locations (9/11; Figure 9). Both younger and older 
patients had difficulties maintaining fixation. Fewer patients produced clear deficits for the top target 
location (4/11). However, even in this condition all patients were below the TD mean (solid line, Figure 
9). When fixation time was averaged across the 4 target locations, 8/11 patients exhibited clear fixation 
duration deficits (zpi > 2).  
The best model describing group differences between MPS-IVa and TD groups was a model 
that included all 2-way interactions: Group X Age, Group X Condition, and Condition X  Age.  The 
Condition X Age  interaction was already apparent in the TD data.  The Group X Condition interaction 
reflects differences between quadrants that were larger for MPS-IVa patients than controls.  Control 
differences were relatively modest (maximum difference, top vs bottom = 160 msec), but patient 
differences were more pronounced (maximum difference, also top vs bottom, 906 msec).  The Group X 
Age interaction occurred because there were larger differences between groups at younger ages, but the 
model without this interaction was nearly equivalent, so its influence is weak (∆AIC=2.1).  The 
strongest difference, which is also reflected in model values, however, is that patients held fixation on 
the target for considerably less (1082 msec) than would be predicted for controls, and a model without 
the Group term was poor (Condition X Age model, ∆AIC = 55). 
________________ 
Figure 10 about here 
________________ 
 
Tyrosinemia Type III (T3) 
 T3 patient fixation dwell times are presented in Figure 10. As a group, the patients were 
shifted below the TD mean (Average zpi < 0 in 9/10 patients), but fewer patients were clearly outside the 
control range (Average zpi < -2 in 2/10 patients).   Shorter fixations were more common to top and 
bottom targets (4 / 10 patients zpi < -2), but the short fixation times were not always in the same 
individuals.  
Page 23 of 64
URL: http://mc.manuscriptcentral.com/pcgn
Cognitive Neuropsychology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Cognitive function in Morquio and Tyrosinemia  Page 24  
 
 The best model for data from patients and TD controls included 2 two-way interactions:  
Condition X Age and Condition X Group.   The Condition X Group interaction reflects differences 
between quadrants that were larger in patients (maximum difference of 158 msec in controls compared 
to 528 msec in patients).  In general, the differences between T3 patients and controls were smaller and 
less prevalent compared to MPS-IV.   In fact, if the three T3 patients with the shortest fixation times are 
removed, the T3 patient group is not different from controls (the best model includes a Condition X Age 
interaction, but no term for Group).  When these patients are included, however, there is a group effect 
(model without Group, ∆AIC = 17).  Together, both the individual and group results show that most T3 
patients were not different from controls, but there were some exceptions. 
Fixation Task – Intrusive Saccades 
Typically Developing Controls 
The frequency of intrusive saccades during the period in which participants were supposed to 
hold fixation was defined by a quadratic function. Figure 11 shows that intrusive saccades decrease with 
age, with the majority of age-related change occurring before 10 years. A model which included a 
Condition X Age interaction (∆AIC / AICw = 0 / .99) was clearly better than a model that did not 
(∆AIC / AICw = 8 / .01). Examination of systematically grouped trajectories revealed that, similar to 
the related measure of fixation time, there was a distinct developmental trajectory for the top target 
location (Top vs others model, ∆AIC / AICw = 0.00 / 0.54; separate quadrant model, ∆AIC / AICw = 
0.38 / .44). The average number of intrusive saccades at 6 years was fewest for the top target location 
(top position, 1.72 fixations, vs maximum of 2.03 fixations for the right position).  The difference 
between locations was smaller by 15 years (right position, 0.92, vs maximum of 1.07 fixations for the 
left position). 
___________________ 
Figure 11 about here 
___________________ 
 
Morquio syndrome (MPS-IVa) 
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MPS-IVa patients often exhibited more intrusive saccades than TD controls (Figure 11). Five of 
the 11 patients were more than 2 zpi from controls.  These 5 patients, not surprisingly, also had shorter 
fixation durations.  Fixation durations would be expected to be shorter when there are intrusive 
saccades. Three patients, however, did not have deficits in both measures: patient 2 (6.44 years), 7 (9.84 
years) and 8 (11.71 years).  They were within the control range for intrusive saccades but not fixation 
time.  This means the first fixation on the target was shorter than in controls, but there were not more 
saccades in general, and patients did not go back and forth between the target and other locations.  They 
held fixation for a shorter time on the target and then moved away.  Sample plots from horizontal and 
vertical trials in two patients and age-matched controls are shown in Figure 12. These illustrate the 
saccade and fixation deficits reported in these patients.  
________________ 
Figure 12 about here 
________________ 
The best model included an interaction between Age and Condition, and a main effect of 
Group. Intrusive saccade suppression was poorer in MPS-IVa patients compared to TD controls, 
regardless of the target location. On average, MPS-IVa patients made 0.67 more intrusive saccades than 
would be predicted for TD controls. 
________________ 
Figure 13 about here 
________________ 
Tyrosinemia III (T3) 
 Individual T3 intrusive saccade data is presented in Figure 13. Unlike MPS-IVa, intrusive 
saccade frequencies were normal in the majority of T3 patients (9/10 patients zpi range -2 to 2). One 
older patient (patient 9) had more substantial problems across target locations and, therefore, for 
performance collapsed across locations (zpi  = -5.64). Importantly, patient 9 also exhibited fixation time 
deficits, and it is clear from the eye movement traces that fixation on the target was disrupted by 
intrusive saccades made towards the screen centre (Figure 14).  
________________ 
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Figure 14 about here 
________________ 
T3 and control fixation count data was best explained a model with Group X Age and Condition 
X Age interactions, but the weakness of the group effect is evident, because a model with only a 
Condition X Age interaction is essentially equivalent (∆AIC = .05).  The Group X Age interaction 
occurs because the young T3 patients make somewhat fewer saccades than controls, while the older T3 
patients make somewhat more.  The Condition X Age interaction was evident in the control data.  
 
Pro-saccade Task – Saccade Onset time 
Typically Developing Controls 
Figure 15 plots saccade onset times for TD controls (solid grey line). Similar to simple reaction 
times, saccade onsets decreased with age and the majority of change occurred between 5 and 12 years. 
Saccade onset times were log transformed because residuals for raw values increased at higher values.  
There was a clear preference for a model that included an Age
 
X Condition interaction. Inspection of 
systematic differences between target locations revealed that development was best described by a 
model with independent trajectories for top and bottom target locations, and a shared trajectory for 
horizontal target locations. Bottom target onsets were longest at 6 years (max bottom, 307 ms vs min 
right, 247 ms).  At older ages the differences narrow and the order changes (max top, 186 ms vs min 
right, 161 ms at 19 years). 
________________ 
Figure 15 about here 
________________ 
Morquio patients (MPS-IVa) 
Individual MPS-IVa saccade onset values are shown in Figure 15. Averaged across target 
locations, all patients had zpi less than 2. Borderline deficits were found for 3 patients on left targets 
(patient 2, 10 and 11) and 2 patients for top targets (patients 8 and 11). The best model for saccade onset 
included an interaction between Group and Condition, in addition to the interaction between Age and 
Condition that was noted in controls. The interaction results from control/patient differences that differ 
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by quadrant, although the means across quadrants are very similar (patients 19 msec faster than controls 
in the bottom quadrant and 34 msec slower in the left quadrant; overall means differ by less than 1 
msec).  There was no evidence for a main effect of group independent of the interaction with condition. 
The model with just an Age X Condition interaction was better than the model that included an Age X 
Condition interaction and a main effect of Group (∆AIC = 1.39). 
________________ 
Figure 16 about here 
________________ 
Tyrosinemia type III 
Individual T3 saccade onset values are shown in Figure 16.  Averaged across target locations, 
only one patient (patient 9, 17.98 years) had a zpi > 2. Patient 9 also had fixation time and intrusive 
saccade deficits.  Models of saccade onset did not support differences between patients and controls. 
The best model did not include a Group term. 
 In sum, neither patient group was systematically slower to initiate saccades. 
Pro-saccade Task – Saccade Peak Velocity 
There was no evidence of differences in saccade velocity when either patient group was 
compared to controls. The preferred model for MPS-IVa patients and controls included a Condition X 
Age interaction, but no effect of group.  For T3 patients, the model with only a Condition X Age 
interaction was essentially equivalent to the best model, which was more complex and, as a result, less 
preferred (∆AIC=0.6; best model = Condition X Age + Condition X Group).   
 
Discussion 
We examined cognitive functioning in two rare inherited metabolic diseases – Morquio 
syndrome (MPS-IVa) and tyrosinemia type III. We compared patients to controls using formal tools for 
model selection and a developmental trajectory approach. This provides a richer way of evaluating 
developmental differences than traditional age-matched comparisons.  We were able to separate 
different types of developmental effects, including changes to the rate of development and constant 
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decrements in performance in the presence of normal rates of developmental change.  We included both 
analysis of group performance and individual comparisons (whether individuals are inside or outside 
the control range defined by model prediction intervals), which contribute different, but complimentary 
information (see discussion below). 
In both diseases we found cognitive effects, but with different functional profiles. Attentional 
control was consistently affected in Morquio patients and language in Tyrosinemia.  These are good 
candidates for sensitive markers of disease progression and they document selective functional impacts 
that can be integrated with descriptions of biological change. A summary of effects across cognitive 
domains is shown in Table 1. 
  MPS-IVa (Morquio Syndrome) 
Few studies have investigat d cognitive performance in Morquio syndrome (MPS-IVa), 
primarily because clinical observations report normal intellectual function (Dvorak-Ewell et al., 2010; 
Wraith, 2006).  A recent study, however, reported mild cognitive changes (Davison et al., 2013) and 
highlighted difficulties with attention.   We did more detailed cognitive testing and found attention 
deficits in several tasks.   Fixation was disrupted by intrusive saccades and visual search times were 
slower, but without a decrease in search efficiency, which is consistent with a problem at a control stage 
rather than a problem in allocating attention during the search process.  An analysis of reaction time 
distributions showed that the problem was not occasional lapses of attention, but slowing that affects 
both fast and slow reaction times.  This implicates a stage that is always present, but is not sensitive to 
the attentional demands of the display (e.g. a decision stage, rather than a search stage).  Two patients 
had elevated search slopes but most did not.  These findings support and expand on the Davison et al. 
(2013) study, where parents of MPS-IVa patients reported difficulties with concentration and attention.  
The fixation task, in particular, may index the same phenomena reported by parents, since 
concentration problems could be the everyday consequence of the same issue that is evident in 
maintaining attention on a target during formal testing.   Intrusive saccades and shorter fixation times 
may not simply reflect a problem that is isolated to eye-movement control.  The cortical areas that are 
responsible for maintaining fixation (Krauzlis, Goffart, & Hafed, 2017), including areas in dorso-lateral 
prefrontal cortex, the frontal eye fields and the superior colliculus, are areas that have connections to 
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other modalities:  auditory or proprioceptive, in the case of the frontal eye fields (Medendorp, 
Buchholz, Van Der Werf, & Leoné, 2011); movement control, in the case of the superior colliculus 
(Krauzlis et al., 2017).  The frontal eye fields, for example, are thought to “encode ‘supramodal’ 
representations to guide attention and behaviour” (Medendorp et al., 2011).  Problems in these areas 
would plausibly lead to both difficulties with eye-movement control and to more general attentional 
issues. 
Several areas implicated in fixation are also involved in visual search, where MPS-IVa patients 
had slowed responses in the presence of mostly normal search efficiencies.  The frontal eye fields are 
associated with the production of exploratory eye movements during search (Booth et al., 2003), and 
dorsolateral and dorsomedial prefrontal cortex are involved in response decisions (Venkatraman, 
Rosati, Taren, & Huettel, 2009).    The network of common areas would be a candidate system to 
examine for changes to brain function in MPS-IVa.   
In sum, our results highlight difficulties with control aspects of attentional tasks in MPS-IVa.  
They extend the preliminary results reported by Davison et al. (2012) and they show that the differences 
in attentional tasks occur without commensurate changes in other cognitive tasks (e.g. language) or 
general slowing (as reflected in normal or near normal simple reaction time, saccade onset and saccade 
velocity). 
Tyrosinemia III (T3) 
 In Tyrosinemia III, there were clear deficits in that both language production (BNT) and 
comprehension (BPVS), where 6 / 10 (55%) and 8 / 11 (73%) patients were clearly outside the control 
range and nearly all patients produced low scores compared to controls. These differences appeared to 
widen with age because the largest differences were found in older patients. There were also some 
differences in visual search, where overall visual search time was slower in 5 / 11 (45%) patients.  The 
additional time needed for complex displays was not different from controls (like MPS-IVa), but the 
differences increased for slower reaction times, suggesting occasional attentional failures (unlike MPS-
IVa).  Differences in the attention tasks were present in the youngest and eldest patients.   
 To our knowledge, this study represents the most detailed cognitive assessment of T3 
patients to date and highlights, especially, language impairments and some attentional effects along 
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with possible age-related decline. Our results provide formal tests to confirm and extend the case-based 
findings of Ellaway et al. (2001), who described mild to moderate intellectual impairments in a sample 
of 12 patients, but without specific information about cognitive testing.   
The prevalence language deficits in T3 is interesting since this is a frequently reported cognitive 
feature of  NTBC treated T1 patients (Bendadi et al., 2014; Thimm et al., 2011). NTBC inhibits 4-
hydroxyphenylpyruvate dioxygenase, blocking the biochemical pathway in T1 at the same place where 
it is blocked in T3 and leading to greatly increased blood tyrosine levels. In essence, T1 patients 
become T3 patients with this treatment, except that T1 patients are also subjected to other potential 
collateral effects of NTBC.   
 The biochemical mechanism that explains the cognitive deficits of T3 patients is 
currently unknown, but in T1 patients, impairments are only present after NTBC treatment, which raises 
tyrosine levels.  Learning impairments are also present in the mouse model of T1 when treated with 
NTBC, but not in wild type mice treated with NTBC, suggesting that the metabolic result of treating T1 
with NTBC causes the impairment,  rather than treatment with NTBC directly (Hillgartner et al., 2016).  
Since T3 results in the same metabolic outcome as T1 treated with NTBC, our results support the same 
conclusion. In addition, Ellaway et al. (2001) reported that T3 patients who were diagnosed and put on a 
low tyrosine diet when they were older presented with more severe symptoms than patients who began 
a low tyrosine diet earlier and they voiced the suspicion that elevated tyrosine levels in cerebrospinal 
fluid (CSF) are particularly damaging during infancy.  Our study did not analyze biochemical data, but 
some of the variance in the cognitive performance in patients in our sample could result from individual 
differences in tyrosine levels that, in turn, are based on variations in early exposure or dietary 
compliance. Relating tyrosine concentrations at different ages to cognitive performance in future work 
will be an important step to understanding how and when tyrosine affects the brain and when dietary 
control is critical for effective treatment. 
The behavioural consequences for T1 mice treated with NTBC are worth noting in 
relationship to the language deficits we found.  Hillgartner et al (2016) found that NTBC treated T1 
mice were slower to learn in a maze task.  Both the BNT and the BPVS are tests of vocabulary.  That is, 
they test the facility with which words are stored for the long term in the mental dictionary.  Both tests 
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would be sensitive to problems with word learning.  This means it may be that word learning, rather 
than language, per se, is what is impaired in our T3 patients.  
The cognitive neuropsychology of metabolic disease  
Our results show that neurodegeneration from metabolic disease is not a uniform process.  
We did not find a homogeneous set of general effects, nor an additive set of effects that increased with 
severity.  Instead, different diseases had specific selective impacts on language or attention.   Since the 
different metabolic diseases affect different chemical systems in the brain, this shows that neuro-
cognitive systems are not just differentiated by location.  Populations that are critical for different 
cognitive functions are differentially sensitive to cellular support systems.  Cognitive 
neuropsychological assessment of metabolic disease (or other diseases that affect the cellular 
environment) can begin to ask “why?”  Are there systems, for example, that are particularly sensitive to 
neural transmission speed,  network synchronization, particular neurotransmitters, growth or membrane 
changes—all properties that would be directly influenced by the biochemical environment?   What is 
the functional aspect of the system that makes these characteristics critical?  This is a relatively 
unexplored dimension, within neuropsychology, that is orthogonal to the understanding of anatomical 
networks.  These questions will be critical, however, to understanding the brain as an integrated 
biochemical and anatomical system and they will be critical to our understanding of disease. 
For MPS-IVa, what we can say about the relationship between metabolic processes and 
cognition is limited because it has typically been described as a condition that doesn’t have cognitive 
impacts.  As a result, there has been little effort to explain how a deficiency in N-acetylgalactosamine-6-
sulfatase (GALNS) might affect the brain.  Davison et al. (2013) were probably the first to offer some 
possibilities.  GALNS breaks down karatan sulfate and chondroitin-6-sufate, and these help coordinate 
neuroaxonal connection formation (Miller, Sheppard, & Pearlman, 1997).  In addition, Davison 
speculate that MPS IVa may affect calcium signalling, and connections between calcium signalling, 
mitochondria and neurodegeneration have been made for Huntington’s disease, amyotrophic lateral 
sclerosis, Alzheimer’s disease and Parkinson’s disease (Marambaud, Dreses-Werringloer, & Vingtdeux, 
2009).  Calcium signalling plays an important role in long term potentiation and excitotoxicity, two 
different routes to cognitive effects (Marambaud et al., 2009). 
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In tyrosinemia type III, there is a more interesting story and a more developed context.  T3 
involves a defect in the enzyme, 4-hydroxyphenylpyruvate dioxygenase, which is needed to break down 
tyrosine, the precursor of dopamine and norepinephrine.  There are several possible ways this might 
lead to cognitive effects, as outlined by Hillgartner et al.  (2016), who set out to explain cognitive 
effects in NTBC treated patients with tyrosinemia type I (T1; recall that NTBC blocks tyrosine 
metabolism at the same point affected in T3).  With a defective enzyme of tyrosine catabolism, tyrosine 
accumulates.   This could produce several primary changes in the brain:  1) increased tyrosine; 2) 
increased dopamine (as a result of conversion from tyrosine); 3) decreased large amino acids (like 
tryptophan, the precursor of serotonin) that are outcompeted by tyrosine; 4) decreased serotonin (due to 
lack of precursor).  Each of these could create its own effects.  Hillgartner et al., however, propose that 
the real source of cognitive problems in treated T1 is not a consequence of any of these primary effects, 
but via two by-products of defective tyrosine break-down:  one that is neurotoxic (succinylacetone) and 
the other that is both neurotoxic and causes demyelination (δ-ALA).       
This is a perfectly reasonable hypothesis for cognitive effects in NTBC treated T1.  
Hillgartner et al. propose that NTBC is poorly transported into the brain, so that tyrosine catabolism 
proceeds past the point where NTBC stops it in the body and neurotoxic by-products will result.  The 
problem is that this hypothesis cannot explain cognitive effects in T3.   The enzyme that is defective in 
T3 acts at the same point that NTBC acts, but it will be defective in all cells, including those in the 
brain.  This means the toxic by-products that Hillgartner et al., identify will not be produced in T3, but 
cognitive decline still occurs.  There must be a separate mechanism for cognitive decline to explain T3 
(perhaps related to the primary effects), and if this yet-to-be-identified mechanism explains cognitive 
decline in T3 it could also explain what appear to be similar cognitive problems in T1.  The mechanism, 
however, can not be based on catabolism that proceeds past the point where the defect occurs in T3. 
The tyrosinemia study illustrates how specific information about cognitive impairments in 
metabolic disease (the similarity of impairments in T3 and NTBC-treated T1), together with 
information about the metabolic pathways affected, might influence our understanding of the link 
between cognitive and biochemical mechanisms, even if there are many outstanding questions (e.g. Are 
T1 and T3 really showing the same pattern of cognitive impairments when both are tested in sufficient 
Page 32 of 64
URL: http://mc.manuscriptcentral.com/pcgn
Cognitive Neuropsychology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Cognitive function in Morquio and Tyrosinemia  Page 33  
 
detail? What is the link between primary biochemical effects and the specific cognitive problems, 
concentrated on learning or language, that we observed?) 
Clinically, our results, and, more generally, the results from cognitive testing reported in 
this special issue, are important because they can be used to anticipate the kinds of problems patients 
and families might expect and can inform choices about how to support patients.  Specific cognitive 
capacities that are impacted by disease are also important to identify when choosing measures to use for 
monitoring patients or for assessing new treatments.  Since oculomotor or attentional tasks show the 
biggest impacts in MPS-IVa, for example, and language tasks show the largest changes in T3, these 
would be the best initial candidates for monitoring. 
 Cognitive neuropsychology of development 
 Even though detailed cognitive assessment of the populations we have presented is at an 
early stage, it is clear that the cognitive neuropsychology of development presents both challenges and 
opportunities (see also, for example, Pitchford & Funnell, 1999).  Development involves both changes 
over time and potential dependencies among changing capacities.  Theories of development must 
specify the time course of intrinsic or environmentally conditioned change, the environmental inputs 
that are required for development, and potential dependencies among capacities.   The pattern of 
dependencies that support successful development is not guaranteed to persist at the same level, or 
persist at all, when the system is mature, which means that development cannot be transparently 
inferred from either the mature system or insults to that system.   
The complexity of the relationship between adult and developmental models can be illustrated, in 
terms that will be familiar to readers of Cognitive Neuropsychology, in the domain of reading.  It is 
relatively clear, from cognitive neuropsychological results, that sub-lexical and lexical mechanisms for 
reading are largely independent components in the mature system and all major reading models include 
them (Coltheart, Rastle, Perry, Langdon, & Ziegler, 2001; Harm & Seidenberg, 1999; Zorzi, 2010).   
The relative independence of these systems in adulthood, however, does not mean that they are 
independent during development.  This is apparent from developmental dyslexia (e.g. Hulme & 
Snowling, 2016) or more directly, in the context of the current discussion, from acquired dyslexia after 
a stroke in childhood (Pitchford & Funnell, 1999).   As they have in other areas of neuropsychology, the 
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consequences of brain damage can reveal properties of components and dependencies in a 
developmental (rather than a static) model that are not available in other ways.  Although there are 
many studies of developmental cognitive difficulties, the approach that involves characterising 
components and dependencies in a detailed developmental cognitive model, of the sort that readers of 
Cognitive Neuropsychology would find familiar, is relatively underdeveloped.  Our results are too 
preliminary to show this promise except in outline, but they do show that developmental effects from 
metabolic disease can be selective enough to allow tests of functional models and they illustrate both 
some methodological issues and some approaches that offer solutions. 
One of the basic problems is that development is a moving target.  The statistical models of 
developmental trajectories that we have introduced here provide some solutions.  They allowed us to 
compare patients and controls across a range of ages when performance is changing and to separate 
offsets, which create differences across all ages, from changes to developmental rates.   Offsets 
characterised MPS-IVa attentional changes (in both visual search and fixation tasks) while a change to 
the rate of development characterised T3 language results, where there was age-related decline. 
Capturing developmental trajectories becomes an even more powerful tool when longitudinal data 
are available.  Individual patient trajectories can be compared to control trajectories and variance in 
rates of development in the patient group will show whether there is, for example, consistent decline, or 
heterogeneity in the effects of disease over time.  If patients need to be tracked clinically, individual 
longitudinal trajectories could conceivably show that patients are not following the normal course of 
development far before their performance is different from controls at any single point in time, 
providing a more sensitive test of disease progression. 
The issue of sensitivity and the contrast between what is apparent in individual data and group data 
is already clear with our samples.  Effects in some individuals that do not occur in all individuals in the 
group are common.  Data from a group of patients, however, can also show that there are deficits even 
when the individual data do not.   Conjunction search results for the MPS-IVa patients were a case in 
point.  Only 3 of the patients were outside the control range as individuals, but the population, as a 
whole, was clearly shifted toward slower RTs, with only two patients faster than the control mean.  
There is a very low probability that so many scores would be slower the control mean in an unimpaired 
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sample.  This is clinically important because it highlights the limits of individual samples for some 
questions (i.e. is there impairment from disease in this group or not) and also reinforces the point that 
techniques like longitudinal sampling may be needed to detect decline at the earliest possible moment  
at the individual level. 
The statistical approach we have adopted is a powerful method to deal with developmental data and 
with relatively small samples.    There are, however, limits that small samples, inevitable in rare 
diseases, impose.  We cannot, for example, say very much about whether a group trajectory derived 
from cross-sectional patient data is a good representation of how diseases progress in individual 
patients, and we have avoided fitting a trajectory to the patient group.  In a small sample, with relatively 
high variability, the precise shape, inclination or location of the trajectory can be highly unstable and 
shows, again, the need for longitudinal data.  When the changes over time are clearer, as in the T3 
language data, the statistical models allow clear conclusions based on the interaction between group and 
age.  Even when this is the case, however, the precise location or shape of the trajectory may be 
relatively uncertain. 
Conclusion 
Our study introduces new data and methods to illustrate the promise of characterising neuropsychological effects 
in inherited metabolic diseases. Two patient cohorts showed that the cognitive effects of disease were not 
homogeneous. Specific measures that were identified as sensitive for each disease could be developed 
further into new tools that help track disease progress or quantify treatment benefits. In addition, our data 
are a promising basis for understanding the biochemical and individual factors that influence the severity 
and time course of developmental effects. Finally, they make several extensions possible. Cognitive 
performance can be related to changes in structure, activity or biochemistry as measured by MRI, fMRI, 
MRS or EEG to triangulate the biological basis of cognitive changes.  A fuller understanding of 
population and individual profiles, extending the methods described here to longitudinal data, will be a 
necessary next step for understanding the cognitive impacts of disease, the best methods for tracking 
disease progression and the most sensitive indicators of treatment success. 
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Table 1: Summary of cognitive deficits across cognitive domains 
Task
Number of patients 
with scores worse 
than control mean
Number of 
patients with 
zpi  > 1
Number of 
patients with 
zpi  > 2
Evidence of 
group 
difference?
Number of patients 
with scores worse 
than control mean
Number of 
patients with 
zpi  > 1
Number of 
patients with 
zpi  > 2
Evidence of 
group 
difference?
11/12 3/12 0/12 weak 7/11 4/11 3/11 yes
Visual search
Overall 
search time 11/12 7/12 6/12 yes 7/11 6/11 4/11
yes for 
older 
patients
Effect of 
display size 7/12 5/12 3/12 no 1/11 1/11 0/11 no
Overall 
search time 10/12 7/12 3/12 yes 7/11 7/11 5/11 yes
Effect of 
display size 6/12 2/12 2/12 no 4/11 3/11 1/11 no
Language
Boston 
Naming Test 7/11 4/11 1/11 no 9/10 8/10 6/10 yes
BPVS 9/11 7/11 0/11 weak 11/11 10/11 7/11 yes
Oculomotor tasks
Fixation task
Dwell time 11/11 10/11 8/11 yes 9/10 6/10 2/10 weak
Intrusive 
saccades 9/11 7/11 5/11 yes 3/11 2/11 1/11 no
Prosaccade task
Onset time 5/9 1/9 0/9 no 5/9 2/9 1/9 no
Saccade velocity 6/9 1/9 0/9 no 1/9 0/9 0/9 no
MPS-IVa Tyrosenimia III
Feature search
Simple reaction time
Conjunction search
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Figure 1. Mean simple reaction time for MPS-IVa patients (filled circles) and typically developing controls (open 
circles). The developmental trajectory for controls is plotted as a solid line with 95% prediction intervals (dashed lines).   
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Figure 2. Mean simple reaction time for T3 patients (filled circles) and TD controls (open circles). The developmental 
trajectory for controls is plotted as a solid line with a 95% prediction intervals (dashed lines).  
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Figure 3. Overall mean RT and search efficiencies (display size slopes) in a visual search task for MPS-IVa patients 
(filled circles) and controls (open circles).   Feature search results are in the left panels and conjunction search on the 
right.  The developmental trajectory for controls are is plotted as a solid line with 95% prediction intervals (dashed 
lines). The red dotted line in the efficiency plots represents efficient search (no increase in reaction time for larger 
displays).  
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Figure 4. MPS-IVa and Control reaction times from feature and conjunction search.  Reaction times are displayed in 
quintile bins along with the difference between quintile means for patients and controls (control value = 0).  Differences 
between means were standardised by the standard error from the control bin.   Note change in scale for final two 
difference plots.  
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Figure 5.  Overall mean RT and search efficiencies (display size slopes) in a visual search task for T3 patients (filled 
circles) and controls (open circles).   Feature search results are in the left panels and conjunction search on the right.  
The developmental trajectory for controls are is plotted as a solid line with 95% prediction intervals (dashed lines). The 
red dotted line in the efficiency plots represents efficient search (no increase in reaction time for larger displays).  
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Figure 6. Tyrosinemia III and Control reaction times from feature and conjunction search.  Reaction times are displayed 
in quintile bins along with the difference between quintile means for patients and controls (control value = 0).  
Differences between means were standardised by the standard error from the control bin.  Note change in scale for final 
two difference plots. 
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Figure 7. Scores for MPS-IVa patients and controls on the Boston Naming Test (BNT; production) and British Picture 
Vocabulary Scale (BPVS; comprehension). Patients are filled circles and typically-developing controls are open circles.  
Typically developing trajectories (solid line) and 95% prediction intervals are included (dashed lines).  
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Figure 8. Scores for Tyrosenimia III patients and controls on the Boston Naming Test (BNT; production) and British 
Picture Vocabulary Scale (BPVS; comprehension). Patients are filled circles and typically-developing controls are open 
circles.  Typically developing trajectories (solid line) and 95% prediction intervals are included (dashed lines).  
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Figure 9. Fixation dwell time for MPS-IVa patients (filled circles) and TD controls (open circles). Typically developing 
trajectories (solid line) and 95% prediction intervals (dotted lines) are included. 
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Figure 10. Fixation dwell time for Tyrosinemia III patients (filled circles) and TD controls (open circles). Typically 
developing trajectories (solid line) and 95% prediction intervals (dotted lines) are included.  
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Figure 11.  Number of intrusive saccades for MPS-IVa patients (filled circles) and TD controls (open circles). Typically 
developing trajectories (solid line) and 95% prediction intervals (dotted lines) are included. 
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Figure 12.  Fixation task saccades over time for MPS-IVa patients 7 and 11. The visual stimulus (blue line) is presented 
along with eye position of the patients (black line) and age-matched TD controls (red dashed line). Both patients showed 
fixation duration deficits buts only patient 11 displayed an elevated intrusive saccade count. Patient 7 disengages before 
the end of the trial. 
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Figure 13.  Number of intrusive saccades for Tyrosinemia III patients (filled circles) and TD controls (open circles). 
Typically developing trajectories (solid line) and 95% prediction intervals (dotted lines) are included. 
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Figure 14. Fixation task saccades over time fo  T3 patient 9. The visual stimulus (blue line) is presented along with eye 
position of the patient (black line) and age-matched controls (dashed red line). 
  
Page 57 of 64
URL: http://mc.manuscriptcentral.com/pcgn
Cognitive Neuropsychology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
 
Figure 15. Average saccadic onset time (SaccOnset) for MPS-IVa patients (black dots) and TD controls (outlined grey 
dots). Horizontal target locations are shown in the top row of graphs and vertical target locations are shown in the 
bottom row of graphs. The typical developmental trajectory (grey solid line) is expressed as a quadratic function. 95% 
confidence limits (grey dashed-line) are presented. 
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Figure 16. Average saccadic onset time (SaccOnset) for T3 patients (black dots) and TD controls (outlined grey dots). 
Horizontal target locations are shown in the top row of graphs and vertical target locations are shown in the bottom row 
of graphs. The typical developmental trajectory (grey solid line) is expressed as a quadratic function. 95% confidence 
limits (grey dashed-line) are presented.  
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Appendices 
Appendix 1.  MPS-IVa and Tyrosinemia III patient demographics 
 
Group PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
MPS-Iva 1 M 5.27 4.02 BL – English / Pashto 
MPS-Iva 2 F 6.44 5.00 BL – English / Pashto 
MPS-IVa 3 F 6.48 5.07 BL – Pashto / English 
MPS-IVa 4 M 7.77 8.02 BL – English / Pashto 
MPS-IVa 5 F 9.33 8.07 BL – Pashto / English 
MPS-IVa 6 F 9.79 10.08 ML – English 
MPS-IVa 7 M 9.84 7.07 BL – Manderin / English 
MPS-IVa 8 M 10.28 7.06 BL – Pashto / English 
MPS-IVa 9 M 11.71 15.10 ML - English 
MPS-IVa 10 M 11.78 7.10 ML - English 
MPS-IVa 11 F 12.05 11.04 BL – English / Pashto  
MPS-IVa 12 M 14.39 11.03 BL – English / Pashto 
      
T3 1 F 4.42 5.32 BL – English / Pashto 
T3 2 M 5.23 3.08 BL – Pashto / English 
T3 3 F 6.28 5.32 BL – English / Punjabi 
T3 4 M 6.62 9 ML - English 
T3 5 F 7.48 5.92 BL – English / Pashto 
T3 6 F 7.83 5.00 BL – Pashto / English 
T3 7 M 8.25 2.92 BL – English / Pashto 
T3 8 M 15.81 5.32 BL – English / Pashto 
T3 9 M 17.68 7.92 BL – Pashto / English 
T3 10 F 19.52 6.08 BL – English / Punjabi 
T3 11 F 19.81 10.32 BL – English / Punjabi 
Note: ML, Monolingual, BL, Bilingual 
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Appendix 2.  MPS-IVa model results 
Model 
AIC ΔAIC 
Akaike 
Weight 
     
 
Simple RT 
  Condition X Age + Age X Group -458.7 0.0 0.23 
Condition X Age + Group -458.7 0.0 0.22 
Condition X Age -458.5 0.2 0.20 
 
Condition X Age + Age X Group + Condition X Group -455.8 2.8 0.05 
 
Condition X Age + Condition X Group -455.8 2.9 0.05 
Age X Group -455.4 3.3 0.04 
Feature search 
  
Age + Group 3162.8 0.0 0.36 
 
Group X Age 3164.2 1.3 0.18 
Display Size² + Age + Group 3164.5 1.7 0.15 
Display Size² X Age + Group X Age + Display Size² X Group 3169.5 6.7 0.01 
 
Conjunction search 
  
  
Display Size X Age + Group X Age 5539.5 0.0 0.19 
Display Size + Age X Group 5539.5 0.0 0.19 
Display Size X Age + Group 5540.2 0.8 0.13 
Display Size + Age + Group 5540.3 0.8 0.13 
 
Display Size X Age + Group X Age + Display Size X Group 5541.3 1.8 0.08 
 
Display Size X Age X Group 5543.1 3.6 0.03 
Boston Naming Test 
Age 560.5 0.0 1.00 
 
Age X Group 829.3 268.8 0.00 
     British Picture Vocabulary Scale 
Age X Group 829.3 0.0 0.53 
Age + Group 830.0 0.7 0.38 
 
Age 833.0 3.6 0.09 
 
Group 1004.8 175.5 0.00 
Fixation dwell time 
Condition X Age + Age X Group + Condition X Group 16713.0 0.0 0.52 
 
Condition X Age X Group 16714.1 1.2 0.29 
 
Condition X Age + Condition X Group 16715.0 2.1 0.18 
Condition X Age + Age X Group 16721.7 8.8 0.01 
Intrusive saccades 
  
Condition X Age + Group 1734.9 0.0 0.29 
 
Condition X Age + Condition X Group 1735.1 0.3 0.26 
Condition X Age + Age X Group 1736.0 1.1 0.17 
Condition X Age + Age X Group + Condition X Group 1736.1 1.2 0.16 
Condition X Age X Group 1738.2 3.3 0.06 
     
 
Saccade onset 
  Condition X Age + Condition X Group -977.0 0.0 0.58 
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Condition X Age + Age X Group + Condition X Group -975.0 2.0 0.21 
Condition X Age -972.8 4.2 0.07 
Saccade velocity 
  
Condition X Age 15446.6 0.0 0.63 
 
Condition X Age + Group 15448.5 2.0 0.24 
Condition X Age + Age X Group 15450.2 3.7 0.10 
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Appendix 3.  Tyrosinemia III model results. 
Model 
AIC ∆AIC 
Akaike 
Weight 
     Simple RT 
Condition X Age X Group -422.1 0.00 0.45 
Age + Group -420.1 1.97 0.17 
 
Age + Group + Condition -419.5 2.60 0.12 
 
Age X Group -418.5 3.63 0.07 
Feature search 
Group X Age 3232.2 0.0 0.29 
 
Group X Age + Display Size X Group 3233.1 0.9 0.18 
 
Display Size + Age X Group 3233.2 1.1 0.17 
Display Size X Age + Group X Age + Display Size X 
Group 3233.7 1.6 0.13 
 
Display Size X Age + Group X Age 3233.8 1.6 0.13 
 
Display Size X Age X Group 3235.4 3.2 0.06 
Conjunction search 
Display Size + Age + Group 5565.7 0.00 0.18 
 
Display Size + Age X Group 5565.8 0.07 0.17 
 
Display Size X Age + Group 5566.5 0.81 0.12 
Display Size X Age + Group X Age 5566.6 0.87 0.11 
Display Size X Group + Age 5567.2 1.47 0.09 
Group X Age + Display Size X Group 5567.2 1.52 0.08 
 
Display Size + Age 5568.0 2.29 0.06 
Display Size X Age + Group X Age + Display Size X 
Group 5568.0 2.31 0.06 
Display Size X Age X Group 5568.7 2.97 0.04 
 
Display Size X Age 5568.8 3.08 0.04 
     Boston Naming Test 
Age X Group 532.6 0.0 0.93 
Age + Group 537.8 5.2 0.07 
 
Age 566.4 33.8 0.00 
 
Group 593.9 61.4 0.00 
British Picture Vocabulary Scale 
Age X Group 807.3 0.0 0.93 
 
Age + Group 812.5 5.2 0.07 
 
Age 876.6 69.3 0.00 
Group 975.7 168.4 0.00 
Fixation dwell time 
  
Condition X Age + Condition X Group 16009.9 0.0 0.34 
 
Condition X Age X Group 16010.2 0.3 0.29 
Condition X Age + Group 16011.2 1.3 0.18 
Condition X Age + Age X Group + Condition X Group 16011.9 2.0 0.13 
Condition X Age + Age X Group 16013.2 3.3 0.07 
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Intrusive saccades 
  Condition X Age + Age X Group 1645.5 0.0 0.29 
Condition X Age 1645.6 0.0 0.28 
Condition X Age X Group 1646.9 1.4 0.15 
 
Condition X Age + Group 1647.4 1.9 0.11 
 
Age + Condition 1649.2 3.7 0.05 
Saccade onset 
Condition X Age -975.4 0.0 0.51 
 
Condition X Age + Group -974.1 1.3 0.26 
 
Condition X Age + Age X Group -972.1 3.3 0.10 
Saccade velocity 
Condition X Age + Condition X Group 15455.0 0.0 0.36 
 
Condition X Age 15455.8 0.8 0.24 
 
Condition X Age + Group 15456.2 1.2 0.19 
Condition X Age + Age X Group + Condition X Group 15457.0 2.0 0.13 
Condition X Age + Age X Group 15458.2 3.2 0.07 
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